Podcast appearances and mentions of helen mcshane

Lucinda Rouse and Dami Adewale are joined by Helen McShane, director of research, innovation and systems change at Young Lives vs Cancer.Helen explains how Young Lives vs Cancer came to launch an innovation lab, with the aim of using its assets as a trusted charity brand to support the development of early stage business ventures that align with its mission of supporting children and young people with cancer.She describes the challenges associated with carving out time and space to work on long-term innovative solutions as a charity supporting the immediate and urgent needs of people in crisis.Tell us what you think of the Third Sector Podcast! Please take five minutes to let us know how we can bring you the most relevant, useful content. To fill in the survey, click here. Hosted on Acast. See acast.com/privacy for more information.

Clinical Trials Of Vaccines With Prof. Helen McShane

Helen McShane discusses her work leading the TB vaccine research program at Oxford University, and shares her thoughts on the challenges facing vaccine development and eradication of this disease.

A career in juggling, organisation and guilt management Professor Helen McShane has been working on a new TB vaccine for 10 years. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. She developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. Developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy.

A career in juggling, organisation and guilt management Professor Helen McShane has been working on a new TB vaccine for 10 years. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. She developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. Developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy.

A career in juggling, organisation and guilt management Professor Helen McShane has been working on a new TB vaccine for 10 years. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. She developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. Developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy.

Helen McShane from the University of Oxford discusses results from a phase IIb tuberculosis trial.

What are the best ways to control the global problem of tuberculosis? Professor Helen McShane from the Jenner Institute tells us about the MVA85A tuberculosis vaccine from her lab that’s currently undergoing large-scale clinical trials and the impact it could have on the incidence of TB around the world. This episode of Microbe Talk has been produced for World TB Day on Saturday 24 March.

Dr Helen McShane has been working on a new TB vaccine for 10 years. She explains why developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. Dr Helen McShane developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. BCG, now over 100 years old, remains the only licensed vaccine against Tuberculosis. It confers good protection against severe disease and meningitis but doesn't protect against lung disease. MVA85A was the first vaccine of the new generation to enter into efficacy testing. It is currently being tested in The Gambia, Senegal and South Africa.

Dr Helen McShane has been working on a new TB vaccine for 10 years. She explains why developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy. There are about 9 million new cases and 1.7 million deaths every year from tuberculosis. Dr Helen McShane developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. BCG, now over 100 years old, remains the only licensed vaccine against Tuberculosis. It confers good protection against severe disease and meningitis but doesn't protect against lung disease. MVA85A was the first vaccine of the new generation to enter into efficacy testing. It is currently being tested in The Gambia, Senegal and South Africa.

Professor Helen McShane talks about her work on a new vaccine against tuberculosis. There are about 9 million new cases and two million deaths every year from tuberculosis (TB). BCG, now over 100 years old, remains the only licensed vaccine against TB. It confers good protection against severe disease and meningitis, but doesn't protect against lung disease. After working on TB for 10 years, Professor Helen McShane developed MVA85A, a vaccine with the aim to boost the cellular immune response induced by BCG. Professor McShane explains why developing countries are especially in need of a new vaccine since HIV and TB epidemics overlap and show a devastating synergy.

Helen McShane and Dr Helen Fletcher talk about a new TB vaccine currently being developed at Oxford's Wellcome Trust Centre that could become a more effective vaccine against Tuberculosis.